Sign in Subscribe
Diseases

Capsida Initiates Phase 1/2 Study for Gene Therapy CAP-003 for Parkinson's Disease

Strategic Insights

— 1 min read

Capsida Biotherapeutics, a clinical-stage genetic medicines company, has announced the clearance of the Investigational New Drug (IND) application for CAP-003, a potential best-in-class intravenously administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This milestone marks the second wholly owned clinical program developed by Capsida to receive IND clearance. The Phase 1/2 study aims to initiate patient dosing in the third quarter of this year, addressing the substantial unmet need in PD-GBA treatment.

Key Takeaways:

  • CAP-003, a proprietary IV-delivered gene therapy, targets the GCase protein to slow or halt disease progression in PD-GBA patients.
  • The treatment demonstrated dose-dependent increases in GCase activity in critical brain regions, exceeding the 30% efficacy threshold in non-human primate studies.
  • The Phase 1/2 study will assess the safety and efficacy of CAP-003, with the first patient expected to be dosed in the third quarter of this year.
  • PD-GBA is characterized by a 30% GCase activity deficit, with currently no approved treatments targeting this enzyme.
  • Capsida's proprietary capsid and cargo technology aim to safely cross the blood-brain barrier, addressing previous limitations in treatment development.
  • The company's clinical pipeline includes promising treatments for rare and common diseases, with IND clearance for CAP-002 and CAP-003.
  • Capsida has established partnerships with AbbVie, Lilly, and CRISPR Therapeutics, and was founded in 2019 by Versant Ventures and Westlake Village BioPartners.

Statistics:

  • Up to 15% of Parkinson's patients have mutations in the GBA gene.
  • Patients with PD-GBA demonstrate a roughly 30% GCase activity deficit compared to healthy individuals.
  • Phase 1/2 clinical trials for CAP-003 are expected to initiate in the third quarter of this year.
  • CAP-003 has demonstrated dose-dependent increases in GCase activity in non-human primate studies.

Sources:

  • Capsida Biotherapeutics press release, June 2025.
  • https://www.businesswire.com/news/home/20250611109903/en/
  • "GBA mutations are associated with an increased risk for Lewy body dementia and age-related death through reduction of glucocerebrosidase activity." (Source: Lyras et al., 2019.)

Read more